Bio Pharma Dive

AUGUST 16, 2023

The new coupons include some of the most commonly prescribed diabetes drugs from Eli Lilly, Novo Nordisk and Sanofi.

Insulin 130

Insulin Pharmacy Manufacturing Drugs 130

STAT News

JANUARY 20, 2023

In an attempt to tackle the root causes of inflated insulin prices, the state of California filed a lawsuit last week accusing drug manufacturers and pharmacy benefit managers of artificially and illegally jacking up the price of insulin. The sausage-making of how insulin is priced is not for the faint of heart.

Insulin 105

Insulin Pharmacy Manufacturing Drugs 105

STAT News

APRIL 21, 2023

WASHINGTON — Amid a scramble to assemble a health care policy package in the Senate, a pair of key senators have significantly changed a proposal to cap insulin costs. The new legislation by Senate Diabetes Caucus co-chairs Sens. Jeanne Shaheen (D-N.H.)

Insulin 98

Insulin Packaging Packaging Pharmacy 98

pharmaphorum

APRIL 13, 2022

The treatment has been around for over a century but insulin has still become the centre of the ongoing discussion over pricing of pharmaceutical products. Ben Hargreaves looks at why insulin’s price is so controversial and whether this could be set to change. Insulin rationing. In the US, approximately 37.3

Insulin 130

Insulin Drugs Production Hormones 130

pharmaphorum

JANUARY 13, 2023

The ‘big three’ insulin producers Novo Nordisk, Eli Lilly, and Sanofi are being sued by the state of California for allegedly working together to set artificially inflated prices for their products. The suit follows legal action over insulin pricing taken by other states, including Arkansas , Kansas, Mississippi, and Minnesota.

Insulin 105

Insulin Manufacturing Production Pharmacy 105

STAT News

JANUARY 12, 2023

The California attorney general has filed a lawsuit accusing several drugmakers and pharmacy benefit managers of conspiring to set prices for insulin, joining a growing list of states that have taken such a step as more and more Americans struggle to afford the life-savings diabetes treatment.

Insulin 105

Insulin Pharmacy 105

Drug Channels

APRIL 26, 2022

In this issue: Green Monster : The 340B market hits new highs in 2021 Not-Free Agents : Big 340B profits for CVS, Walgreens, Express Scripts, et al Batter Up : Fixing the insulin market Pinch Hitters : Walgreens bets on robots Plus, Dr. Glaucomflecken helps UnitedHealthcare celebrate Doctors’ Day! Hope to see you there!

Pharmacy 79

Pharmacy Insulin Doctors Doctor 79

STAT News

MARCH 27, 2023

The Ohio attorney general filed a lawsuit on Monday accusing three large pharmacy benefit managers of fixing prices for various medicines, the latest effort to scrutinize the controversial companies that occupy a crucial role in pharmaceutical pricing.

Pharmacy 111

Pharmacy Drugs Insulin Medicine 111

Drug Channels

MARCH 28, 2023

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook. Below, I highlight four takeaways from this year’s lists, including a look at biosimilar insulin and the forthcoming biosimilar competition for Humira.

Insulin 95

Insulin Pharmacy Containment Drugs 95

Drug Channels

JANUARY 9, 2024

For 2024, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)—have again each excluded 600 or more drugs from their standard formularies. You can find our updated counting below. Read on for my deep dive into these two therapeutic categories.

Insulin 87

Insulin Pharmacy Drugs Production 87

Drug Channels

MAY 10, 2023

Yesterday’s reflections on Asembia’s Specialty Pharmacy Summit included a link to the general session slides. My portion of the deck included an updated mapping of vertical integration among insurers, PBMs, specialty pharmacies, and providers within U.S. drug channels. Many readers asked for a standalone version of this infamous chart.

Pharmacy 91

Pharmacy Insulin Drugs 91

Drug Channels

JANUARY 10, 2023

For 2023, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)—have again increased the number of drugs they exclude from their standard formularies. Each exclusion list now contains about 600 products.

Insulin 91

Insulin Pharmacy Containment Drugs 91

Drug Channels

APRIL 3, 2024

For 2024, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)—have again each excluded 600 or more drugs from their standard formularies. Click here to see the original post from January 2024. Read on for my deep dive into these two therapeutic categories.

Insulin 52

Insulin Pharmacy Drugs Production 52

The Pharma Data

JULY 29, 2021

Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus. Semglee (insulin glargine-yfgn) is the first interchangeable biosimilar product approved in the U.S.

Insulin 52

Insulin Production FDA Approval Generic Drugs 52

XTalks

SEPTEMBER 23, 2020

Being hailed as the world’s shortest and thinnest needle for insulin injection, Droplet Micron has recently been introduced into the pen needle market by HTL (High Tech Lab)-STREFA, Inc. These are important feature innovations for those that depend on insulin injections. Droplet Micron is now available at local pharmacies.

Insulin 98

Insulin Marketing Drug Delivery Compliance 98

The Pharma Data

SEPTEMBER 30, 2021

Lilly’s Insulin Lispro Injection, 100 units/mL — first introduced at half the list price of branded Humalog® (insulin lispro injection, 100 units/mL) in 2019 — will now have a 70 percent lower list price than Humalog U-100 starting January 1, 2022 Insulin Lispro Injection can be ordered through all U.S.

Insulin 52

Insulin Pharmacy Branding Medicine 52

Drug Channels

NOVEMBER 23, 2021

In this issue: The State of Specialty Pharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble Reconsidering Amazon P.S. Please join the nearly 13,000 consumers of my daily commentary and links to neat stuff at @DrugChannels on Twitter. Happy Thanksgiving, everyone!

Insulin 80

Insulin Pharmacy Drugs 80

Drug Channels

MARCH 21, 2023

Join me for my new live video webinar, Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook , on March 31, 2023, from 12:00 p.m. Spring is here in sunny downtown Philadelphia, worldwide headquarters of Drug Channels. Join my more than 38,000 LinkedIn followers for daily links to neat stuff. to 1:30 p.m.

Insulin 76

Insulin Drugs Pharmacy 76

Drug Channels

NOVEMBER 23, 2021

In this issue: The State of Specialty Pharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon P.S. Please join the nearly 13,000 consumers of my daily commentary and links to neat stuff at @DrugChannels on Twitter.

Insulin 76

Insulin Pharmacy Drugs 76

STAT News

MARCH 10, 2023

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather abbreviated this time around due to a Woodstock-like gathering for health journos.

Insulin 96

Insulin Pharmacy Pharma Companies Drugs 96

Pharmacy Checkers

NOVEMBER 19, 2020

Forgetting about the potential dangers to competition from corporate Leviathan Amazon, that it launched a new online pharmacy this week will certainly appeal to tens of millions of Americans. But, unlike in many other industries where Amazon can crush the competition on prices, its online pharmacy launch does not accomplish that.

Pharmacy 52

Pharmacy Insulin Branding Generic Drugs 52

Drug Channels

NOVEMBER 22, 2021

In this issue: The State of Specialty Pharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon Plus, the FDA preps you for Thursday with a regulatory soup review. Happy Thanksgiving, everyone!

Insulin 76

Insulin Pharmacy Drugs 76

Drug Channels

NOVEMBER 23, 2021

In this issue: The State of Specialty Pharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon P.S. Please join the nearly 13,000 consumers of my daily commentary and links to neat stuff at @DrugChannels on Twitter.

Insulin 52

Insulin Pharmacy Drugs 52

Drug Channels

SEPTEMBER 2, 2020

I'm rerunning this post to provide context for manufacturers' recent actions regarding 340B contract pharmacies. Yesterday, Eli Lilly announced that its products can be dispensed only at covered entities and their child sites, but not via external pharmacies. per 3 mL pen or $0.10 per 10 mL vial.

Pharmacy 52

Pharmacy Insulin Manufacturing Drugs 52

STAT News

NOVEMBER 17, 2022

… UnitedHealth Group’s pharmacy benefits manager, OptumRx, will keep AbbVie’s Humira alongside up to three biosimilar medicines next year, Bloomberg News writes. pharmacy benefit manager and managed $112 billion in drug spending last year, will place biosimilars on its formulary in the same position as Humira.

Insulin 96

Insulin Pharmacy Sales Medicine 96

XTalks

FEBRUARY 8, 2024

In its 2022 financial report, Sanofi reported that sales of the long-acting insulin dropped 27.6 percent in the US, impacted by prior formulary losses as well as “erosion of the basal insulin market,” the company said in the statement. In its 2022 financial report, Sanofi reported that sales of the long-acting insulin dropped 27.6

Sales 52

Sales Insulin FDA Approval Drugs 52

Drug Channels

JANUARY 19, 2022

For 2022, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)— increased the number of drugs they excluded from their standard formularies. Each exclusion list contains 400 to 500 products. Let me know what you think by commenting below or on social media.

Insulin 93

Insulin Pharmacy Containment Drugs 93

XTalks

JANUARY 5, 2024

Among its services, Lilly said LillyDirect provides disease management resources that include access to independent healthcare providers, personalized support and direct delivery of select Lilly medications to homes via third-party pharmacy dispensing services.

Drugs 59

Drugs Pharmacy Cosmetics Insulin 59

pharmaphorum

JANUARY 28, 2021

One of these markets is the insulin market. Up until now, the insulin market has experienced little competition and, as a result, prices have soared over the years. Currently, more than seven million patients rely on insulin, and that number is growing each year. But, that will soon be changing, due to biosimilars.

Marketing 97

Marketing Insulin HR Production 97

Drug Channels

MARCH 30, 2023

This week, I’m rerunning some popular posts while I prepare for tomorrow’s live video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook. Its strategy echoes the pricing of the first interchangeable insulin biosimilars— as I predicted in 2021. In February, AbbVie stated that U.S.

Insulin 85

Insulin Pharmacy Drugs Sales 85

Drug Channels

APRIL 20, 2022

For 2022, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)— increased the number of drugs they excluded from their standard formularies. Click here to see the original post and comments from January 2022.

Insulin 82

Insulin Pharmacy Containment Drugs 82

STAT News

NOVEMBER 18, 2022

Diabetic patients will now have easier access to insulin after the FDA approved an Eli Lilly biosimilar as interchangeable with the biologic drug , Bloomberg News notes. Rezvoglar,

Insulin 98

Insulin FDA Approval Production Pharmacy 98

Drug Channels

DECEMBER 16, 2020

I expect manufacturers to escalate their challenges to the contract pharmacy elements of the program. Meanwhile, covered entities will be battling manufacturers, state Medicaid programs, their contract pharmacy partners, and perhaps even HRSA itself. The 340B program will be a major issue in 2021.

Pharmacy 52

Pharmacy Insulin Manufacturing Drugs 52

XTalks

JUNE 5, 2023

GLP-1 stimulates insulin production, thus reducing blood glucose levels, and it interacts with the brain to suppress appetite and create a feeling of fullness. mg and 1 mg doses will be available to wholesalers for distribution to retail pharmacies. Despite this, Novo Nordisk doesn’t anticipate interruptions in supplying 1.7

FDA Approval 98

FDA Approval Containment Drugs Pharmacy 98

XTalks

FEBRUARY 8, 2021

As a subset of biosimilars, interchangeable biological products can be substituted for the reference product at the pharmacy level, without the input of the prescribing physician. Significantly, insulin was deemed to be a biologic as of March 23, 2020, making it a reference product for the development of biosimilar versions.

Production 78

Production Insulin Branding Generic Drugs 78

Drug Channels

SEPTEMBER 15, 2020

Last Friday, The Wall Street Journal published my opinion piece: The Federal Program That Keeps Insulin Prices High. I summarize issues with the role of contract pharmacies in the 340B Drug Pricing Program. The article text is pasted below for those who don't subscribe.

Pharmacy 52

Pharmacy Insulin Sales Drugs 52

pharmaphorum

APRIL 1, 2022

Semglee (insulin glargine-yfgn) is the first biosimilar available at the retail pharmacy counter, and it obtained interchangeable status. And, manufacturers will likely pay close attention to the impact of Semglee’s interchangeable designation on the adoption of biosimilars in the retail pharmacy space.

Marketing 59

Marketing Pharmacy FDA Approval Manufacturing 59